Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5% – Should You Sell?

Shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) fell 1.5% during mid-day trading on Monday . The stock traded as low as $4.90 and last traded at $4.9240. 137 shares were traded during trading, a decline of 97% from the average session volume of 4,685 shares. The stock had previously closed at $5.00.

Analyst Ratings Changes

Several equities analysts recently commented on MOLN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. JPMorgan Chase & Co. lowered their price target on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a report on Monday, December 8th. Finally, HC Wainwright assumed coverage on shares of Molecular Partners in a report on Tuesday, January 27th. They set a “buy” rating and a $13.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.58.

Molecular Partners Price Performance

The stock has a market cap of $198.83 million, a PE ratio of -2.56 and a beta of 1.07. The stock has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $4.06.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors and hedge funds own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.